Cargando…
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
Autores principales: | Hughes, Derralynn A., Nicholls, Kathleen, Sunder‐Plassmann, Gere, Jovanovic, Ana, Feldt‐Rasmussen, Ulla, Schiffmann, Raphael, Giugliani, Robert, Jain, Vipul, Viereck, Chris, Castelli, Jeffrey P., Skuban, Nina, Barth, Jay A., Bichet, Daniel G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593787/ https://www.ncbi.nlm.nih.gov/pubmed/30920142 http://dx.doi.org/10.1002/ajmg.a.61105 |
Ejemplares similares
-
Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2021) -
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
por: Hughes, Derralynn A, et al.
Publicado: (2023) -
Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial
por: Schiffmann, Raphael, et al.
Publicado: (2018) -
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
por: Hughes, Derralynn A, et al.
Publicado: (2017) -
Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
por: Germain, Dominique P., et al.
Publicado: (2019)